Items where authors include "Maughan, TS"

Article

Henderson, RH, French, D, McFerran, E et al. (10 more authors) (2022) Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer. Journal of Cancer Policy, 33. 100342. ISSN 2213-5383

Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745

Richman, SD orcid.org/0000-0003-3993-5041, Hemmings, G, Roberts, H et al. (12 more authors) (2022) FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology. ISSN 0021-9746

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Yin, J, Cohen, R, Jin, Z et al. (23 more authors) (2021) Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute. ISSN 0027-8874

Malla, SB, Fisher, DJ, Domingo, E et al. (29 more authors) (2020) In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer. Clinical Cancer Research. ISSN 1078-0432

Craig, SG, Humphries, MP, Alderdice, M et al. (21 more authors) (2020) Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 123. pp. 1280-1288. ISSN 0007-0920

Pulsawatdi, AV, Craig, SG, Bingham, V et al. (10 more authors) (2020) A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 14 (10). pp. 2384-2402. ISSN 1574-7891

Burzykowski, T, Coart, E, Saad, ED et al. (24 more authors) (2019) Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2 (9). e1911750.

Salem, ME, Yin, J, Weinberg, BA et al. (18 more authors) (2018) Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer, 103. pp. 205-213. ISSN 0959-8049

Sjoquist, KM, Renfro, LA, Simes, RJ et al. (31 more authors) (2017) Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 10 (6). djx253. ISSN 0027-8874

Franko, J, Shi, Q, Meyers, JP et al. (17 more authors) (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. The Lancet Oncology, 17 (12). pp. 1709-1719. ISSN 1470-2045

Smith, CG, Fisher, D, Harris, R et al. (15 more authors) (2015) Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research, 21 (15). pp. 3453-3461. ISSN 1078-0432

Venderbosch, S, Nagtegaal, ID, Maughan, TS et al. (13 more authors) (2014) Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 20 (20). pp. 5322-5330. ISSN 1078-0432

Lieu, CH, Renfro, LA, De Gramont, A et al. (8 more authors) (2014) Association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD clinical trials program. Journal of Clinical Oncology, 32 (27). pp. 2975-2982. ISSN 0732-183X

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Smith, CG, West, H, Harris, R et al. (12 more authors) (2013) Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. Journal of the National Cancer Institute, 105 (16). 1249 - 1253. ISSN 0027-8874

Madi, A, Fisher, D, Wilson, RH et al. (9 more authors) (2012) Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer, 107 (7). pp. 1037-1043. ISSN 0007-0920